ARS Pharmaceuticals (SPRY) Return on Sales (2023 - 2025)
Historic Return on Sales for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 1.64%.
- ARS Pharmaceuticals' Return on Sales rose 88800.0% to 1.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64%, marking a year-over-year increase of 229300.0%. This contributed to the annual value of 0.09% for FY2024, which is 18122600.0% up from last year.
- According to the latest figures from Q3 2025, ARS Pharmaceuticals' Return on Sales is 1.64%, which was up 88800.0% from 3.03% recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Return on Sales ranged from a high of 0.55% in Q4 2024 and a low of 6199.9% during Q1 2024
- For the 4-year period, ARS Pharmaceuticals' Return on Sales averaged around 933.83%, with its median value being 26.99% (2022).
- As far as peak fluctuations go, ARS Pharmaceuticals' Return on Sales tumbled by -52642500bps in 2024, and later surged by 61952400bps in 2025.
- ARS Pharmaceuticals' Return on Sales (Quarter) stood at 26.99% in 2022, then plummeted by -8240bps to 2250.67% in 2023, then soared by 100bps to 0.55% in 2024, then plummeted by -400bps to 1.64% in 2025.
- Its Return on Sales stands at 1.64% for Q3 2025, versus 3.03% for Q2 2025 and 4.66% for Q1 2025.